Indoleamine-Pyrrole 2,3,-Dioxygenase
"Indoleamine-Pyrrole 2,3,-Dioxygenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dioxygenase with specificity for the oxidation of the indoleamine ring of TRYPTOPHAN. It is an extrahepatic enzyme that plays a role in metabolism as the first and rate limiting enzyme in the kynurenine pathway of TRYPTOPHAN catabolism.
Concept/Terms
Indoleamine-Pyrrole 2,3,-Dioxygenase- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Indoleamine-Oxygen 2,3-Oxidoreductase (Decyclizing)
- Indoleamine 2,3-Dioxygenase
- Indoleamine 2,3 Dioxygenase
- IDO Dioxygenase
- Dioxygenase, IDO
- Indolamine-2,3-Dioxygenase
- Indolamine 2,3 Dioxygenase
Below are MeSH descriptors whose meaning is more general than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
Below are MeSH descriptors whose meaning is more specific than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
This graph shows the total number of publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in Harvard Catalyst Profiles by year, and whether "Indoleamine-Pyrrole 2,3,-Dioxygenase" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 0 | 2 |
| 2009 | 4 | 2 | 6 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 1 | 4 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 1 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 6 | 3 | 9 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 4 | 5 |
Below are the most recent publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in Profiles.
-
Indoleamine 2,3-Dioxygenase Deletion to Modulate Kynurenine Pathway and to Prevent Brain Injury after Cardiac Arrest in Mice. Anesthesiology. 2023 11 01; 139(5):628-645.
-
Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging. Blood Adv. 2023 08 22; 7(16):4633-4646.
-
IDO/Kynurenine; novel insight for treatment of inflammatory diseases. Cytokine. 2023 06; 166:156206.
-
Therapeutic potential of bromhexine for acute itch in mice: Involvement of TMPRSS2 and kynurenine pathway. Int Immunopharmacol. 2023 Apr; 117:109919.
-
A novel pathologic marker, indoleamine 2,3-dioxygenase 1, for the cholangiopathy of immune checkpoint inhibitors-induced immune mediated hepatotoxicity as adverse events and the prediction of additional ursodeoxycholic acid treatment. Med Mol Morphol. 2023 Jun; 56(2):106-115.
-
IgG4-related disease is characterised by the overexpression of immunomodulatory proteins. Histopathology. 2022 Oct; 81(4):486-495.
-
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. J Immunother. 2021 09 01; 44(7):264-275.
-
Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas. Int J Mol Sci. 2021 May 23; 22(11).
-
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. Invest New Drugs. 2020 12; 38(6):1784-1795.
-
Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas. Cells. 2020 05 05; 9(5).